I agree that this site is using cookies. You can find further informations here.
X
Facon, T.
223  results:
Search for persons X
?
1

French early nationwide idecabtagene vicleucel chimeric ant..:

Ferment, B. ; Lambert, J. ; Caillot, D....
British Journal of Haematology.  , 2024
Link: https://doi.org/10.1111/..
 
?
2

P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INE..:

Facon, T. ; Plesner, T. ; Usmani, S....
HemaSphere.  7 (2023)  S2 - p. 18-19 , 2023
Link: https://doi.org/10.1097/..
 
?
3

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) ..:

Weisel, K. ; Kumar, S. ; Moreau, P....
HemaSphere.  7 (2023)  S2 - p. 14-15 , 2023
Link: https://doi.org/10.1097/..
 
?
4

LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASON..:

Crusoe, E ; Facon, T ; Moreau, P...
Hematology, Transfusion and Cell Therapy.  45 (2023)  - p. S400 , 2023
Link: https://doi.org/10.1016/..
 
?
5

UPDATED PROGRESSION-FREE SURVIVAL AND DEPTH OF RESPONSE IN ..:

Capra, M ; Moreau, P ; Dimopoulos, M...
Hematology, Transfusion and Cell Therapy.  44 (2022)  - p. S249 , 2022
Link: https://doi.org/10.1016/..
 
?
6

P851: TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MUL..:

Hasan Bou Issa, L. ; Fléchon, L. ; Laine, W....
HemaSphere.  6 (2022)  - p. 745-746 , 2022
Link: https://doi.org/10.1097/..
 
?
7

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS ..:

Quach, H. ; Leleu, X. ; Mateos, M.-V....
HemaSphere.  6 (2022)  - p. 798-799 , 2022
Link: https://doi.org/10.1097/..
 
?
8

S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANT..:

Hasselbalch Riley, C. ; Hutchings, M. ; Yoon, S.-S....
HemaSphere.  6 (2022)  - p. 81-82 , 2022
Link: https://doi.org/10.1097/..
 
?
9

P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN ..:

Nooka, A. ; Lonial, S. ; Grosicki, S....
HemaSphere.  6 (2022)  - p. 829-830 , 2022
Link: https://doi.org/10.1097/..
 
?
10

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-R..:

Facon, T. ; Kumar, S. K. ; Plesner, T....
HemaSphere.  6 (2022)  - p. 826-827 , 2022
Link: https://doi.org/10.1097/..
 
?
11

S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM TH..:

Dekhtiarenko, I. ; Lelios, I. ; Attig, J....
HemaSphere.  6 (2022)  - p. 74-75 , 2022
Link: https://doi.org/10.1097/..
 
?
12

P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF..:

van de Donk, N. W. C. J ; Popat, R ; Hulin, C...
HemaSphere.  6 (2022)  - p. 14-15 , 2022
Link: https://doi.org/10.1097/..
 
?
13

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZO..:

Quach, H. ; Nooka, A. ; Samoylova, O....
Hematology, Transfusion and Cell Therapy.  42 (2020)  - p. 253-254 , 2020
Link: https://doi.org/10.1016/..
 
?
14

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMI..:

Maiolino, A. ; Moreau, P. ; Dimopoulos, M....
Hematology, Transfusion and Cell Therapy.  42 (2020)  - p. 262-263 , 2020
Link: https://doi.org/10.1016/..
 
?
15

Isatuximab plus carfilzomib and dexamethasone vs. carfilzom..:

Turgut, M. ; Moreau, P. ; Dimopoulos, M....
Hematology, Transfusion and Cell Therapy.  42 (2020)  - p. 51-52 , 2020
Link: https://doi.org/10.1016/..
 
1-15